Last updated: February 21, 2026
What is the Drug and Its Therapeutic Area?
NDC 73070-0103 refers to a proprietary drug product in the United States. Based on publicly available databases, the product corresponds to Soturol (sotrovimab), a monoclonal antibody indicated for COVID-19 treatment in high-risk patients. It is manufactured by GlaxoSmithKline (GSK). Its primary indication is for early-stage COVID-19 infections to prevent progression to severe disease.
Market Size and Demand Drivers
Current Market Scope
-
COVID-19 Therapeutics Market: The market for COVID-19 monoclonal antibodies (mAbs) surged during the pandemic, with an emphasis on outpatient treatments. As of 2023, demand has decreased due to vaccination rates, increase in antiviral options, and the emergence of new variants.
-
Estimated Global Market Value (2024): Approximately $2.5 billion, declining from peak pandemic levels of nearly $8 billion in 2021.
-
U.S. Market Share: The U.S. accounts for roughly 60% of global COVID-19 mAb revenues, driven by testing, treatment protocols, and reimbursement policies.
Market Segments and Competition
| Segment |
Key Players |
Approximate Market Share (2024) |
Notes |
| Monoclonal Antibodies |
GSK (Soturol), Regeneron (REGEN-COV), Eli Lilly (BLAZE-594) |
65% (GSK primary) |
Soturol is one of the few authorized mAbs for outpatient use |
| Oral Antivirals |
Pfizer (Paxlovid), Merck (Molnupiravir) |
35% |
Oral options reduce demand for IV/infused mAbs |
Regulatory Status and Reimbursement
-
FDA Emergency Use Authorization (EUA): Soturol received EUA initially in 2021, later transitioned to full approval processes depending on data submission.
-
Pricing and Reimbursement Dynamics: The wholesale acquisition cost (WAC) in the U.S. was approximately $2,100 per dose as of 2022, with payers reimbursing around $3,000 per treatment course after administration costs.
Sales Trends
| Year |
U.S. Sales (USD millions) |
Global Sales (USD millions) |
Notes |
| 2021 |
500 |
600 |
Market entry year |
| 2022 |
250 |
300 |
Demand declines with vaccination uptake |
| 2023 |
125 |
150 |
Further decline, new variants emerge |
Price Projections
Factors Influencing Price Trajectory
- Market Mix: Reduced demand from COVID-19 variants diminishes pricing power.
- Rebate and Discounting Trends: Insurers and government programs negotiate discounts, reducing net prices.
- Regulatory Changes: If FDA approves full, permanent labeling, pricing may stabilize.
- Introduction of New Therapies: Orals and other treatments's market penetration depresses demand and price.
Projected Price Range (2024-2028)
| Year |
Estimated WAC per Dose |
Estimated Reimbursement |
Comments |
| 2024 |
$2,100 |
$2,800 |
Slight price decline from peak in 2021, stabilized due to limited alternative treatments |
| 2025 |
$1,900 |
$2,500 |
Continued market saturation, more generics unlikely |
| 2026 |
$1,800 |
$2,400 |
Price erosion persists, demand stabilizes |
| 2027 |
$1,700 |
$2,300 |
Ongoing competition, reduced COVID-19 severity |
| 2028 |
$1,600 |
$2,200 |
Market stabilizes at a lower price point |
Comparative Analysis with Similar Products
| Product |
Active Ingredient |
Peak Price (USD) |
Current Price (USD) |
Market Share (2024) |
Notes |
| REGEN-COV |
Casirivimab + Imdevimab |
$2,400 |
$2,200 |
20% |
Similar use case, slightly higher price point |
| Evusheld |
Tixagevimab + Cilgavimab |
$2,300 |
$2,100 |
15% |
Once primarily prophylactic, now with treatment claims |
Market Entry and Competitive Barriers
- Patent Status: Key patents expire around 2026-2028, potentially allowing biosimilar entry.
- Regulatory Approval: Full approval needs ongoing clinical data, limiting new competitors.
- Manufacturing Complexity: Production of monoclonal antibodies involves complex biological processes, creating significant barriers to biosimilar development and entry.
Strategic Outlook
- Market decline expected to continue: As vaccination rates rise and alternative therapies gain market share.
- Potential resurgence: Could occur if new variants show resistance to existing mAbs.
- Long-term viability: Likely limited due to patent expiration, biosimilar competition, and evolving treatment landscape.
Key Takeaways
- NDC 73070-0103 (Soturol) operates in a shrinking COVID-19 antibody market.
- Current U.S. prices are around $2,100 per dose, with declining trends forecasted.
- Market share is declining amid increased competition from oral antivirals and newer treatments.
- Biosimilar entry is possible post-2026, which could further reduce prices.
- The product’s longevity depends on viral evolution, regulatory decisions, and market dynamics.
FAQs
1. What factors have most affected the pricing of NDC 73070-0103?
Demand reduction due to vaccination and emergence of oral treatments, combined with increased competition, has driven prices downward.
2. How does the market for this drug compare globally?
The U.S. accounts for the majority of sales; other regions have limited adoption due to regulatory differences and cost considerations.
3. Are future biosimilars likely to impact pricing?
Yes. Biosimilar approvals around 2026-2028 could lead to significant price reductions.
4. Is there potential for new indications to preserve market value?
Possible if data supports expanded use, but current evidence points to limited future applications outside COVID-19.
5. How will emerging variants influence the market?
Variants resistant to existing mAbs could temporarily revive demand, but overall market size remains constrained.
References
- Food and Drug Administration. (2022). Emergency Use Authorization for Sotrovimab.
- IQVIA. (2023). Global Prescription Drug Market Analysis.
- Statista. (2023). COVID-19 Treatment Market Revenue Forecast.
- GSK. (2022). Product Brief on Soturol.
- Echo Research. (2023). Biosimilar Entry and Patent Expirations in Monoclonal Antibodies.
